Information  X 
Enter a valid email address

Angle PLC Ord 10P (AGL)

Date Time Source Announcement
12 Jan 2021 7:00 am
RNS
Change of Auditor
05 Jan 2021 7:00 am
RNS
Issue of Equity
09 Dec 2020 7:00 am
RNS
Parsortix can capture single cancer cell in sample
20 Nov 2020 4:18 pm
RNS
Holding(s) in Company
18 Nov 2020 4:51 pm
RNS
Holding(s) in Company
13 Nov 2020 10:46 am
RNS
Result of General Meeting
03 Nov 2020 2:54 pm
RNS
Director/PDMR Shareholding
29 Oct 2020 7:00 am
RNS
Interim Results
27 Oct 2020 6:28 pm
RNS
Result of Placing & Notice of General Meeting
  7:00 am
RNS
Accelerated bookbuild to raise up to �20m
20 Oct 2020 7:00 am
RNS
Submission accepted by FDA for substantive review
28 Sep 2020 7:00 am
RNS
Issue of LTIP Options and Share Options
  7:00 am
RNS
ANGLE announces completion of FDA submission
23 Sep 2020 7:00 am
RNS
Potential treatment strategy to limit metastasis
11 Sep 2020 3:35 pm
RNS
Holding(s) in Company
  3:30 pm
RNS
Holding(s) in Company
02 Sep 2020 1:49 pm
RNS
Notification of Interim Results and Webcast
  10:00 am
RNS
Holding(s) in Company
27 Aug 2020 3:13 pm
RNS
Result of 2020 Annual General Meeting
18 Aug 2020 9:30 am
RNS
Holding(s) in Company
14 Aug 2020 7:00 am
RNS
Parsortix use to assess response to immunotherapy
06 Aug 2020 12:20 pm
RNS
Holding(s) in Company
05 Aug 2020 7:00 am
RNS
Notice of AGM and Posting of Annual Report
20 Jul 2020 7:00 am
RNS
Study: Parsortix use in metastatic breast cancer
08 Jul 2020 5:35 pm
RNS
Holding(s) in Company
  5:30 pm
RNS
Holding(s) in Company
  5:30 pm
RNS
Holding(s) in Company
25 Jun 2020 7:00 am
RNS
Preliminary Results
22 Jun 2020 7:00 am
RNS
Blood donations recommenced for FDA studies
29 May 2020 7:00 am
RNS
Notice of Results
12 May 2020 7:00 am
RNS
CTC potential as biomarker in MET inhibitor trials
04 May 2020 7:00 am
RNS
Leading cancer centre publishes Parsortix workflow
28 Apr 2020 7:00 am
RNS
Business Update
17 Apr 2020 7:00 am
RNS
Parsortix performance in head and neck cancer
31 Mar 2020 7:00 am
RNS
COVID-19 BUSINESS IMPACT UPDATE
03 Mar 2020 7:00 am
RNS
Assessing risk of brain metastasis in lung cancer
27 Feb 2020 7:00 am
RNS
Parsortix outperforms other CTC systems in RCC
25 Feb 2020 7:00 am
RNS
ANGLE announce Tri-Con presentation with BioView
17 Feb 2020 7:00 am
RNS
Data demonstrates key advantages of Parsortix
11 Feb 2020 7:00 am
RNS
Study demonstrates Parsortix potential in melanoma
03 Feb 2020 9:10 am
RNS
Issue of Equity
30 Jan 2020 7:00 am
RNS
Interim Results
  7:00 am
RNS
Change of accounting reference date
22 Jan 2020 7:00 am
RNS
Successful face-to-face meeting with FDA
08 Jan 2020 12:33 pm
RNS
Notice of Results
23 Dec 2019 9:55 am
RNS
Issue of Equity
07 Nov 2019 7:00 am
RNS
Cancer centre shows Parsortix use in melanoma
30 Oct 2019 2:44 pm
RNS
Result of AGM
  7:00 am
RNS
Q-submission to FDA containing headline data
08 Oct 2019 7:00 am
RNS
Notice of AGM
04 Oct 2019 5:54 pm
RNS
Holding(s) in Company
  7:00 am
RNS
European patent granted for megakaryocyte analysis
13 Sep 2019 7:00 am
RNS
Use of Parsortix in head and neck cancer
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t